Breast cancer is the most common form of cancer in the U.S. According to the National Cancer Institute (NCI), approximately 15 percent of patients with breast cancer have tumors that are HER2-positive.
This summer, the U.S. Food and Drug Administration approved a new breast cancer treatment that aims to reduce the risk of the cancer returning. The drug, neratinib, is intended for patients with early-stage, HER2-positive breast cancer.
NCI estimates approximately 252,710 women will be diagnosed with breast cancer this year, and 40,610 will die of the disease. This approval is a major step forward in helping to improve survival rates in some breast cancer patients.